Maravai Lifesciences Holdings (MRVI) EBT (2020 - 2026)

Maravai Lifesciences Holdings' EBT history runs 7 years deep, the most recent figure standing at -$6.5 million for Q1 2026.

• In Q1 2026, EBT rose 87.61% year-over-year to -$6.5 million; the TTM figure through Mar 2026 stood at -$188.8 million (up 35.29% YoY), while the FY2025 annual figure was -$235.0 million, up 10.14% from the prior year.
• EBT for Q1 2026 stood at -$6.5 million, up from -$63.0 million in the prior quarter.
• The five-year high for EBT was $656.2 million in Q4 2023, with the low at -$172.1 million in Q3 2024.
• The 5-year median for EBT is -$20.6 million (2023), against an average of $39.2 million.
• The sharpest annual moves came in 2023 and 2024: EBT jumped 584.41% in 2023, then tumbled 737.15% in 2024.
• Maravai Lifesciences Holdings' EBT stood at $95.9 million in 2022, then surged by 584.41% to $656.2 million in 2023, then slumped by 107.02% to -$46.1 million in 2024, then slumped by 36.76% to -$63.0 million in 2025, then surged by 89.64% to -$6.5 million in 2026.
• Business Quant data shows MRVI's EBT at -$6.5 million in Q1 2026, -$63.0 million in Q4 2025, and -$45.1 million in Q3 2025.